Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Symp. case 51% primary Improvement Relative Risk Case 27% HCQ  EPICOS  Prophylaxis  DB RCT Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Double-blind RCT 435 patients in Spain (April 2020 - July 2021) Fewer cases with HCQ (not stat. sig., p=0.31) c19hcq.org Polo et al., Clinical Microbiology and.., Aug 2022 Favors HCQ Favors control

Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers

Polo et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.07.006, EPICOS, NCT04334928
Aug 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Early terminated healthcare worker prophylaxis RCT in Spain, showing lower risk of symptomatic cases with HCQ prophylaxis, without statistical significance due to the small number of events.
risk of symptomatic case, 51.0% lower, RR 0.49, p = 0.79, treatment 3 of 224 (1.3%), control 5 of 211 (2.4%), NNT 97, Kaplan–Meier, primary outcome.
risk of case, 27.0% lower, RR 0.73, p = 0.31, treatment 21 of 224 (9.4%), control 23 of 211 (10.9%), Kaplan–Meier.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Polo et al., 5 Aug 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, peer-reviewed, median age 38.0, 189 authors, study period 15 April, 2020 - 11 July, 2021, trial NCT04334928 (history) (EPICOS). Contact: jamo@sanidad.gob.es.
This PaperHCQAll
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers
Rosa Polo, Xabier García-Albéniz, Carolina Terán, Miguel Morales, David Rial-Crestelo, M Angeles Garcinuño, Miguel García Del Toro, César Hita, Juan Luis Gómez-Sirvent, Luis Buzón, Alberto Díaz De Santiago, Jose Pérez Arellano, Jesus Sanz, Pablo Bachiller, Elisa Martínez Alfaro, Vicente Díaz-Brito, Mar Masiá, Alicia Hernández-Torres, Jose M Guerra, Jesús Santos, Piedad Arazo, Leopoldo Muñoz, Jose Ramon Arribas, Pablo Martínez De Salazar, Santiago Moreno, Miguel A Hernán, Julia Del Amo, Julia Del Amo, Rosa Polo, Santiago Moreno, Juan Berenguer, Esteban Martínez, Miguel A Hernán, Pablo Martínez De Salazar, Xabier García De Albéniz
Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.07.006
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
Abella, Jolkovsky, Biney, Uspal, Hyman et al., Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2
Arvelo, None
Causalab, Chan, School of Public Health
Chien, Anderson, Jockusch, Tao, Li et al., Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID
Clososki, Soldi, Da Silva, Guaratini, Lopes et al., None
Copertino, Lima, Duarte, Powell, Ormsby, None
Davis, Ferreira, Denholm, Tong, Clinical trials for the prevention and treatment of COVID-19: current state of play, Med J Aust
Del Amo, Polo, Moreno, Díaz, Martínez et al., Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons, Epidemiology
Del Amo, Polo, Moreno, Díaz, Martínez et al., Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study, Ann Intern Med
Del Amo, Polo, Moreno, Martínez, Cabello et al., None
Elfiky, Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study, Life Sci
Embi, Levy, Naleway, Patel, Gaglani et al., Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults -Nine States, January, MMWR Morb Mortal Wkly Rep
Feng, Bilello, Babusis, Gordon, Tchesnokov et al., NRTIs tenofovir, TAF, TDF, and FTC are inactive against SARS-CoV-2
García-Albéniz, Amo, Polo, Morales-Asencio, Hernán et al., Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ), European Journal of Epidemiology
General De Segovia, -p r o o f References
Hernández-Díaz, Bateman, Straub, Zhu, Mogun et al., Safety of Tenofovir Disoproxil Fumarate for Pregnant Women Facing the Coronavirus Disease 2019 Pandemic, Am J Epidemiol
Jockusch, Tao, Li, Anderson, Chien et al., A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19, Antiviral Res
Lopez, Chiner-Oms, De Viedma, The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant, Nat Genet
Mehra, Desai, Ruschitzka, Patel, RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet
Muñoz-Mateos, Buti, Fernández, Hernández, Bernal, Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients, Journal of Hepatology
Parienti, Prazuck, Peyro-Saint-Paul, Fournier, Valentin et al., Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal J o u r n a l P r e -p r o o f SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial, EClinicalMedicine
Park, Yu, Kim, Kim, Kim et al., Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets, mBio
Patterson, Prince, Kraft, Jenkins, Shaheen et al., Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission, Sci Transl Med
Pilkington, Hill, Hughes, Nwokolo, Pozniak, How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP, J Virus Erad
Ponticelli, Moroni, Hydroxychloroquine in systemic lupus erythematosus (SLE), Expert Opin Drug Saf
Predhomme, Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State, AIDS Res Hum Retroviruses
Rajasingham, Bangdiwala, Nicol, Skipper, Pastick et al., Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial, Clin Infect Dis
Seet, Quek, Ooi, Sengupta, Lakshminarasappa et al., Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial, Int J Infect Dis
Seifert, Chen, Meditz, Castillo-Mancilla, Gardner, None
Skipper, Pastick, Engen, Bangdiwala, Abassi et al., Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial, Ann Intern Med
Twigg, Schnizlein-Bick, Weiden, Valentine, Wheat et al., Measurement of antiretroviral drugs in the lungs of HIV-infected patients, HIV Ther
Wilkin, Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection, J Biomol Struct Dyn
Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zanella, Zizioli, Castelli, Quiros-Roldan, Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit